vidarabine phosphate and Kahler Disease

vidarabine phosphate has been researched along with Kahler Disease in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19901 (25.00)18.7374
1990's3 (75.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Michaeli, J; Niesvizky, R; Siegel, D1
Keating, MJ; McLaughlin, P; Robertson, LE1
Matsukage, A; Ohashi, A; Ono, K; Saneyoshi, M; Takahasi, T; Ueda, T; Yamamoto, A1
Bonnet, JD; Crowley, JJ; Grever, MR; Hynes, HE; Keppen, MD; Kraut, EH; Salmon, SE1

Reviews

1 review(s) available for vidarabine phosphate and Kahler Disease

ArticleYear
Fludarabine phosphate in lymphoma: an important new therapeutic agent.
    Cancer treatment and research, 1996, Volume: 85

    Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Multiple Myeloma; Vidarabine Phosphate; Waldenstrom Macroglobulinemia

1996

Other Studies

3 other study(ies) available for vidarabine phosphate and Kahler Disease

ArticleYear
2-Chlorodeoxyadenosine for multiple myeloma.
    Blood, 1993, Feb-01, Volume: 81, Issue:3

    Topics: Antimetabolites, Antineoplastic; Cladribine; DNA Damage; Humans; Multiple Myeloma; Vidarabine Phosphate

1993
Inhibitory effects of 9-beta-D-arabinofuranosylguanine 5'-triphosphate and 9-beta-D-arabinofuranosyladenine 5'-triphosphate on DNA polymerases from murine cells and oncornavirus.
    Cancer research, 1979, Volume: 39, Issue:11

    Topics: Animals; Arabinonucleotides; Cells, Cultured; Deoxyribonucleotides; Guanosine Triphosphate; Kinetics; Mice; Multiple Myeloma; Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Rats; Rauscher Virus; Substrate Specificity; Vidarabine Phosphate

1979
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.
    Investigational new drugs, 1990, Volume: 8, Issue:2

    Topics: Adult; Aged; Agranulocytosis; Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Administration Schedule; Drug Evaluation; Humans; Middle Aged; Multiple Myeloma; Vidarabine Phosphate

1990